Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

August 13, 2008 13 August, 2008

Sernova Corp.'s Diabetes Technology Featured at International Congress of the Transplantation Society and on CTV National News

London, Ontario --August 13, 2008 - Sernova Corp. (TSX-V: SVA)

Sernova Corp.'s Sertolin technology is being highlighted at the International Congress of The Transplantation Society (TTS) in Sydney, Australia this week, and was also featured on CTV's National News on Sunday night, with the message that Canadian innovation may be changing the face of diabetes forever.

"Our cell replacement technology, Sertolin, could free insulin dependent (Type 1) diabetics from insulin injections forever," said Dr. David White, Principal Researcher for Sernova Corp. and presenter at the TTS international congress. "We are working to change what it means to be a diabetic, and we are doing it today."

Dr. White's presentation at thecongress, and the CTV National News media coverage, both describe the development of Sernova'sinsulin replacement cellular therapy called Sertolin. A small medical device containing two types of mature porcine (pig) cells (islet and Sertoli cells) is implanted just beneath the skin of a Type 1 diabetic's abdomen.The cells produce insulin that is compatible with human insulin, thus reducing or eliminating the need for constant insulin injections. The Sertoli cells protect the islets from attack by the immune system, eliminating the need for anti-rejection drugs that cause significant side effects.

"Sertolin is so important in the fight against diabetes," said Dr. White. "This is not just about insulin; it's about quality of life and reducing the life threatening complications that come along with this disease. Sertolin will make life easier for diabetics. I am proud to see Sernova's important work highlighted at the International Congress of The Transplantation Society in Sydney and featured on the CTV National News."

"Dr. White's invitation to present our Sertolin data in Sydney shows the high degree of scientific interest in our work in the international scientific community,"commented Justin Leushner, President and CEO of Sernova Corp. "We are excited to share our story."

To watch the CTV National News piece --please click on link below research/#clip72928

About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Craig Gauld, Executive Vice President Tel: (519) 858-5126